Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at the following investor conferences during J.P. M ...

We closed the year with a respectable overall performance, even as the market cooled in December. Read more here.

Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

撼讯PowerColor近期在海外市场推出了一款名为ALPHYN AH10的无线游戏耳机，其独特之处在于搭载了50mm动圈单元及独立AMP功放技术，为玩家带来前所未有的 ...

KKR has been a meaningful investment this year, aided by the firm’s well-executed strategy of broad-based expansion. One clear driver is the continued growth of Assets Under Management ((AUM).

Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO ...

Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. The Master Account of the fund returned 2.6% net in the fourth quarter compared to 2.4% for ...

In November, Alphyn announced the first peer-reviewed article published by leading dermatologists in the Journal of Drugs in Dermatology, highlighting the potential of Zabalafin Hydrogel to treat ...

Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...